IS3222A7 - Lyfjablöndur úr sýruóstöðugum efnum til inntöku um munn - Google Patents

Lyfjablöndur úr sýruóstöðugum efnum til inntöku um munn

Info

Publication number
IS3222A7
IS3222A7 IS3222A IS3222A IS3222A7 IS 3222 A7 IS3222 A7 IS 3222A7 IS 3222 A IS3222 A IS 3222A IS 3222 A IS3222 A IS 3222A IS 3222 A7 IS3222 A7 IS 3222A7
Authority
IS
Iceland
Prior art keywords
oral
unstable
substances
medicinal preparations
preparations made
Prior art date
Application number
IS3222A
Other languages
English (en)
Other versions
IS1918B (is
Inventor
Ingmar Lövgren Kurt
Gunnar Pilbrant Åke
Ysumura Mitsuru
Morigaki Satoshi
Oda Minoru
Ohishi Naohiro
Original Assignee
Aktiebolaget Hässle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10597119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS3222(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aktiebolaget Hässle filed Critical Aktiebolaget Hässle
Publication of IS3222A7 publication Critical patent/IS3222A7/is
Publication of IS1918B publication Critical patent/IS1918B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IS3222A 1986-04-30 1987-04-28 Lyfjablöndur úr sýruóstöðugum efnum til inntöku um munn IS1918B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB08610573A GB2189699A (en) 1986-04-30 1986-04-30 Coated acid-labile medicaments

Publications (2)

Publication Number Publication Date
IS3222A7 true IS3222A7 (is) 1987-10-31
IS1918B IS1918B (is) 2004-03-15

Family

ID=10597119

Family Applications (1)

Application Number Title Priority Date Filing Date
IS3222A IS1918B (is) 1986-04-30 1987-04-28 Lyfjablöndur úr sýruóstöðugum efnum til inntöku um munn

Country Status (33)

Country Link
US (1) US4853230A (is)
EP (3) EP0244380B1 (is)
JP (1) JPH0667837B2 (is)
KR (1) KR950004886B1 (is)
CN (1) CN1025151C (is)
AR (1) AR243377A1 (is)
AT (2) ATE139692T1 (is)
AU (1) AU603568B2 (is)
CA (1) CA1302891C (is)
CS (1) CS268535B2 (is)
CY (1) CY1860A (is)
DD (1) DD260222B5 (is)
DE (3) DE3783386T2 (is)
DK (1) DK169987B1 (is)
DZ (1) DZ1078A1 (is)
EG (1) EG18517A (is)
ES (2) ES2089277T3 (is)
FI (1) FI91708C (is)
GB (1) GB2189699A (is)
GR (2) GR890300156T1 (is)
HK (2) HK104095A (is)
HU (1) HU198385B (is)
IE (1) IE61837B1 (is)
IS (1) IS1918B (is)
MY (1) MY102675A (is)
NO (1) NO174952C (is)
NZ (1) NZ220097A (is)
PH (1) PH24440A (is)
PL (1) PL265417A1 (is)
PT (1) PT84786B (is)
SU (1) SU1709894A3 (is)
YU (1) YU46421B (is)
ZA (1) ZA872379B (is)

Families Citing this family (232)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5433959A (en) 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
US6749864B2 (en) * 1986-02-13 2004-06-15 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
CA2032475C (en) * 1989-05-11 1997-12-30 Heiji Ikushima Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
GR1002098B (en) * 1989-06-08 1995-12-28 Squibb & Sons Inc Pharmaceutical composition having good stability
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
IT1245890B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
IT1245891B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali.
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
ZA937382B (en) * 1992-10-06 1994-04-29 Warner Lambert Co Novel composition for peroral therapy of cognitionimpairment and a process therefor
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
TW280770B (is) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ATE414509T1 (de) * 1994-07-08 2008-12-15 Astrazeneca Ab Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
PL186605B1 (pl) * 1995-09-21 2004-01-30 Pharma Pass Llc Tabletka lub mikrotabletka zawierająca rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol oraz sposób wytwarzania tabletek lub mikrotabletek zawierających rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6296876B1 (en) * 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
DE19752843C2 (de) * 1997-11-28 2003-01-09 Byk Gulden Lomberg Chem Fab Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol
AU1671799A (en) * 1997-11-28 1999-06-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Medicament preparation in the form of a tablet or pellet for acid-labile active substances
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
JP4127740B2 (ja) * 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化したベンズイミダゾール系化合物含有組成物
US6328994B1 (en) 1998-05-18 2001-12-11 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US7041313B1 (en) 1998-08-12 2006-05-09 Altana Pharma Ag Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
WO2000022130A2 (en) 1998-10-15 2000-04-20 Chiron Corporation Metastatic breast and colon cancer regulated genes
WO2000026185A2 (en) * 1998-10-30 2000-05-11 The Curators Of The University Of Missouri Omeprazole solution and method of using same
TWI242000B (en) 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
JP2003524389A (ja) 1998-12-16 2003-08-19 カイロン コーポレイション ヒトサイクリン依存的キナーゼ（ｈＰＮＱＡＬＲＥ）
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US6197329B1 (en) 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
CN1361683A (zh) 1999-06-07 2002-07-31 比克·古尔顿·劳姆贝尔格化学公司 含有一种对酸不稳定的活性化合物的新型制剂和药物剂型
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
ATE369857T1 (de) 1999-10-20 2007-09-15 Eisai R&D Man Co Ltd Methode zur stabilisierung von benzimidazol- verbindungen
DE19959419A1 (de) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
PT1248841E (pt) 2000-01-10 2008-09-15 Novartis Vaccines & Diagnostic Genes expressos diferencialmente no cancro da mama
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
US6749867B2 (en) 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
KR20030059318A (ko) 2000-12-07 2003-07-07 알타나 파마 아게 산 불안정성 활성 성분을 포함하는 현탁액 형태의 약학 제제
SI1341524T1 (sl) 2000-12-07 2012-02-29 Nycomed Gmbh Farmacevtski pripravek v obliki paste, ki obsega kislinsko labilno učinkovino
CN100335040C (zh) 2000-12-07 2007-09-05 奥坦纳医药公司 含有酸敏感型活性成分的快速崩解片剂
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
CA2440588C (en) * 2001-03-13 2010-02-09 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US7309783B2 (en) * 2001-05-09 2007-12-18 The University Of Connecticut Mammalian early developmental regulator gene
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US6543389B2 (en) 2001-06-26 2003-04-08 Pfizer Inc. Insecticidal pet collar
US20040062804A1 (en) 2001-09-28 2004-04-01 Der-Yang Lee Modified release dosage forms
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
PT1459737E (pt) * 2001-10-17 2012-11-26 Takeda Pharmaceutical Grânulos contendo um composto químico instável em meio ácido em concentração elevada
ES2198195B1 (es) 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US20050191353A1 (en) * 2002-08-16 2005-09-01 Amit Krishna Antarkar Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles
WO2004016242A2 (en) * 2002-08-16 2004-02-26 Themis Laboratories Private Limited A process for manufacture of stable oral multiple units pharamceutical composition containing benzimidazoles
US7135324B2 (en) * 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
JP4169329B2 (ja) * 2002-10-04 2008-10-22 村樫石灰工業株式会社 消石灰系塗材組成物
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
CA2503150A1 (en) * 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
WO2004066924A2 (en) * 2003-01-24 2004-08-12 Andrx Labs Llc Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
WO2004072061A1 (en) 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
WO2004093875A1 (en) * 2003-04-22 2004-11-04 Dr. Reddy's Laboratories Limited Oral pharmaceutical formulations comprising acid-labile active ingredients and a water-soluble sugar derivate, use thereof and the suitable process for manufacturing these
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
DE10341414A1 (de) * 2003-09-05 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe
US20050053669A1 (en) * 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
EP1670442A4 (en) * 2003-09-19 2011-09-14 Penwest Pharmaceuticals Co DOSAGE FORMS WITH DELAYED RELEASE
AU2004273958A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005046634A2 (de) * 2003-11-14 2005-05-26 Siegfried Generics International Ag Magensaftresistente verabreichungsform
HU227317B1 (en) * 2003-11-25 2011-03-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Enteric coated tablet containing pantoprazole
CN1321642C (zh) * 2003-12-12 2007-06-20 南京长澳医药科技有限公司 泮托拉唑钠肠溶微丸
EP1699458A4 (en) * 2003-12-30 2012-04-25 Reddys Lab Ltd Dr PHARMACEUTICAL COMPOSITION
MXPA06009991A (es) * 2004-03-03 2007-04-10 Teva Pharma Una composicion farmaceutica estable que comprende un farmaco labil acido.
PT1736541E (pt) 2004-03-29 2013-01-31 Galpharma Co Ltd Nova proteína galectina 9 modificada e sua utilização
US7491263B2 (en) 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
PL1746980T3 (pl) 2004-05-07 2012-03-30 Nycomed Gmbh Farmaceutyczna postać dawkowania zawierająca peletki i sposób jej wytwarzania
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2006067599A2 (en) 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
AU2006213439A1 (en) * 2005-01-03 2006-08-17 Lupin Limited Pharmaceutical composition of acid labile substances
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
EP1845982A2 (en) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions prepared by non-aqueous layering process
KR100570446B1 (ko) * 2005-02-14 2006-04-12 지엘팜텍 주식회사 산 불안정성 약리활성물질 함유 장용성 경구용 제제 및 이의 제조방법
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2006111853A2 (en) * 2005-04-18 2006-10-26 Aurobindo Pharma Limited Stable solid dosage forms of acid labile drug
EP1875911A4 (en) * 2005-04-28 2010-03-03 Eisai R&D Man Co Ltd STABILIZED COMPOSITION
US9040564B2 (en) 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
EP1747776A1 (en) * 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising granular pantoprazole
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2634232C (en) 2005-12-28 2013-08-20 Takeda Pharmaceutical Company Limited Method of producing solid preparation disintegrating in the oral cavity
WO2007080601A1 (en) * 2006-01-16 2007-07-19 Jubilant Organosys Limited Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
EP1872778A1 (en) * 2006-06-29 2008-01-02 LEK Pharmaceuticals D.D. Stable pharmaceutical composition with rabeprazole sodium
CA2658804A1 (en) 2006-07-25 2008-01-31 Vecta Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with ppi
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US8352042B2 (en) * 2006-11-28 2013-01-08 The Alfred E. Mann Foundation For Scientific Research Remote controls and ambulatory medical systems including the same
US20110174855A1 (en) * 2006-11-29 2011-07-21 Yakima Products, Inc. Vehicle top carriers
CN101190208B (zh) * 2006-11-30 2011-11-02 石药集团中奇制药技术（石家庄）有限公司 一种含有盐酸度洛西汀的药物制剂及其制备方法
HUE046465T2 (hu) 2006-12-22 2020-03-30 Ironwood Pharmaceuticals Inc Epesavat megkötõ anyagokat tartalmazó készítmények nyelõcsõ-rendellenességek kezelésére
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
US8173158B2 (en) 2007-10-12 2012-05-08 Takeda Pharmaceuticals U.S.A., Inc. Methods of treating gastrointestinal disorders independent of the intake of food
CN101980700A (zh) 2008-02-20 2011-02-23 密苏里大学董事会 包含奥美拉唑和兰索拉唑以及缓冲剂的组合的组合物及其使用方法
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
CA2736547C (en) 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
US20120128764A1 (en) * 2009-02-23 2012-05-24 Aptalis Pharmatech, Inc. Controlled-release compositions comprising a proton pump inhibitor
CN101822671A (zh) * 2009-03-06 2010-09-08 信谊药厂 雷贝拉唑组合物及其制备方法
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
NZ597534A (en) * 2009-06-25 2013-09-27 Pozen Inc Method for treating a patient in need of aspirin therapy
CN101991543A (zh) * 2009-08-10 2011-03-30 杭州赛利药物研究所有限公司 一种奥美拉唑肠溶干混悬剂及其制备方法
JP2011037787A (ja) * 2009-08-13 2011-02-24 Kyorin Pharmaceutical Co Ltd 塩基性薬物のｐＨに依存しない安定放出組成物
EP2319504A1 (en) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
WO2011138797A2 (en) 2010-05-04 2011-11-10 Cadila Healthcare Limited Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US20140328861A1 (en) 2011-12-16 2014-11-06 Atopix Therapeutics Limited Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
KR102160388B1 (ko) 2012-03-19 2020-09-28 버크 인스티튜트 포 리서치 온 에이징 App 특이적 bace 억제제(asbi) 및 이의 용도
WO2013141827A1 (en) 2012-03-21 2013-09-26 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Enteric coated solid pharmaceutical compositions for proton pump inhibitors
WO2014025905A1 (en) 2012-08-07 2014-02-13 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
US9623047B2 (en) 2012-12-27 2017-04-18 Photo Finish Supplements, Llc Composition and method for improving gastrointestinal health of equine
WO2014113377A1 (en) 2013-01-15 2014-07-24 Ironwood Pharmaceuticals, Inc. Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
KR102220259B1 (ko) 2013-02-12 2021-02-25 버크 인스티튜트 포 리서치 온 에이징 Bace 매개 app 처리과정을 조절하는 히단토인
WO2015102829A1 (en) 2013-12-30 2015-07-09 Avery Dennison Corporation Films for printing
WO2015155281A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
WO2015155307A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2016126625A1 (en) 2015-02-03 2016-08-11 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
EP4218739A3 (en) 2016-01-08 2023-08-09 The Regents of The University of California Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN109563089B (zh) 2016-05-12 2023-06-16 巴克老年研究所 促进app正常加工的化合物
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP6981088B2 (ja) * 2017-01-27 2021-12-15 ニプロ株式会社 経口固形製剤
AU2018284335A1 (en) 2017-06-12 2020-01-30 Glytech Llc. Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists
EP3642206A4 (en) 2017-06-23 2021-04-07 The Regents of The University of California IMPROVING THE CAPACITY OF GABA TO MODULATE IMMUNE RESPONSES
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
EA202191983A1 (ru) 2019-01-22 2021-12-01 Аеовиан Фармасьютикалз, Инк. МОДУЛЯТОРЫ mTORC И ИХ ПРИМЕНЕНИЕ
CN114569579B (zh) 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
CN112516100A (zh) * 2020-12-31 2021-03-19 珠海润都制药股份有限公司 一种艾司奥美拉唑镁肠溶片及其制备方法
ES2924573B2 (es) * 2021-03-18 2024-04-24 Aora Health S L Sistema de administracion en multiples sitios para administracion diferencial en el tracto gastrointestinal
CN115715808A (zh) 2021-08-26 2023-02-28 丽珠医药集团股份有限公司 用于干混悬剂的干混悬颗粒及其制备方法和用途
IL315304A (en) 2022-03-04 2024-10-01 Revagenix Inc Broad-spectrum aminoglycoside antibiotics and their uses
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification
US12102693B1 (en) * 2023-08-25 2024-10-01 Nanomedtrix, Llc Pharmaceutical composition with nanoparticle-based drug delivery combined with non-invasive radiographic monitoring model

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540979A (en) * 1948-04-24 1951-02-06 Smith Kline French Lab Enteric coating
GB760403A (en) * 1952-10-16 1956-10-31 Abbott Lab Improvements in or relating to enteric coatings
GB862376A (en) * 1957-10-10 1961-03-08 Pfizer & Co C Sustained release pharmaceutical tablet
US3131123A (en) * 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
GB1190387A (en) * 1966-05-24 1970-05-06 Green Cross Corp Enteric Coated Medicaments
ZA743391B (en) * 1974-05-28 1975-08-27 A Warren Therapeutic products
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS5867616A (ja) * 1981-10-15 1983-04-22 Tanabe Seiyaku Co Ltd 腸溶性マイクロカプセル
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
JPS5920219A (ja) * 1982-07-26 1984-02-01 Shin Etsu Chem Co Ltd 腸溶性コ−テイング製剤の製造方法
DE3233764C2 (de) * 1982-09-11 1987-05-07 R.P. Scherer GmbH, 6930 Eberbach Verfahren zur Herstellung oraler Dosierungseinheiten
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPS6019715A (ja) * 1983-07-12 1985-01-31 Nisshin Flour Milling Co Ltd 安定なイソカルボスチリル製剤
EP0153105B1 (en) * 1984-02-10 1992-09-09 Benzon Pharma A/S Diffusion coated multiple-units dosage form
SE8404065D0 (sv) * 1984-08-10 1984-08-10 Haessle Ab Novel biologically active compounds
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
JPS62277322A (ja) * 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets

Also Published As

Publication number Publication date
HU198385B (en) 1989-10-30
NZ220097A (en) 1990-04-26
HK55497A (en) 1997-05-09
EP0565210A2 (en) 1993-10-13
EP0502556B1 (en) 1996-06-26
US4853230A (en) 1989-08-01
EG18517A (en) 1993-04-30
ES2010648T3 (es) 1994-07-16
CA1302891C (en) 1992-06-09
DE3751851T2 (de) 1996-10-31
CN87103285A (zh) 1987-11-18
CS307387A2 (en) 1989-06-13
CY1860A (en) 1987-04-16
PL265417A1 (en) 1988-07-21
DK215987D0 (da) 1987-04-28
DK215987A (da) 1987-10-31
DE3783386D1 (de) 1993-02-18
ATE186639T1 (de) 1999-12-15
IE61837B1 (en) 1994-11-30
FI91708C (fi) 1994-08-10
GR890300156T1 (en) 1990-03-14
FI871914A (fi) 1987-10-31
CN1025151C (zh) 1994-06-29
DK169987B1 (da) 1995-04-24
EP0565210A3 (is) 1995-06-07
CS268535B2 (en) 1990-03-14
NO871791L (no) 1987-11-02
PH24440A (en) 1990-06-25
DZ1078A1 (fr) 2004-09-13
AU603568B2 (en) 1990-11-22
MY102675A (en) 1992-09-30
AR243377A1 (es) 1993-08-31
DE3751851D1 (de) 1996-08-01
GB8610573D0 (en) 1986-06-04
ES2089277T3 (es) 1996-10-01
EP0502556A1 (en) 1992-09-09
HK104095A (en) 1995-07-07
IE871106L (en) 1987-10-30
EP0244380B1 (en) 1993-01-07
JPH0667837B2 (ja) 1994-08-31
YU46421B (sh) 1993-10-20
IS1918B (is) 2004-03-15
DD260222B5 (de) 1998-07-09
FI91708B (fi) 1994-04-29
ZA872379B (en) 1987-12-30
EP0565210B1 (en) 1999-11-17
DE244380T1 (de) 1990-02-08
KR950004886B1 (ko) 1995-05-15
ES2010648A4 (es) 1989-12-01
HUT44171A (en) 1988-02-29
EP0244380A3 (en) 1988-10-19
SU1709894A3 (ru) 1992-01-30
FI871914A0 (fi) 1987-04-29
DE3783386T2 (de) 1993-05-06
NO174952B (no) 1994-05-02
PT84786A (en) 1987-05-01
AU7192287A (en) 1987-11-05
KR870009718A (ko) 1987-11-30
NO174952C (no) 1994-08-10
ATE139692T1 (de) 1996-07-15
YU68087A (en) 1988-08-31
NO871791D0 (no) 1987-04-29
GB2189699A (en) 1987-11-04
EP0244380A2 (en) 1987-11-04
PT84786B (pt) 1989-12-29
GR3007448T3 (is) 1993-07-30
JPS62258316A (ja) 1987-11-10

Similar Documents

Publication Publication Date Title
IS1918B (is) Lyfjablöndur úr sýruóstöðugum efnum til inntöku um munn
DK195988A (da) Farmaceutisk praeparat indeholdende mikrokapsler
NO854194L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende antracyklinglykosider.
DK413987D0 (da) Farmaceutiske praeparater
NO872551D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
DK652787A (da) Farmaceutiske praeparater
NO874193D0 (no) Farmasoeytiske preparater.
NO874200D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
MX5577A (es) Formulacion farmaceutica
GB8607749D0 (en) Compounds & pharmaceutical preparations
DK447887A (da) Frysetoerrede farmaceutiske praeparater
IT8748554A0 (it) Associazione medicamentosa
NO875359L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
NO872233D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
NO873423D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
DK624587A (da) Farmaceutisk praeparat indeholdende imidazolderivater
DK149588A (da) Xylometazolinholdige farmaceutiske praeparater
ATE64535T1 (de) Xylometazolinhaltige pharmazeutische praeparate.
MX9203545A (es) Formulaciones farmaceuticas.
SE8603912D0 (sv) Farmaceutisk beredning
SE8602975D0 (sv) Farmaceutisk beredning
DK155368C (da) Oxadiazolylpiperidinforbindelser, og farmaceutisk praeparat indeholdende saadanne forbindelser
GB8629234D0 (en) Pharmaceutical preparations
IE861311L (en) Pharmaceutical preparations
GB8630926D0 (en) Pharmaceutical preparations